Ehud Marom

Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel.

Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel.

Stemcell Medicine Ltd. develops and commercializes cellular therapies. It develops products from a number of tissue sources, such as adipose tissue stem cells for ischemic indications and from T cells for solid tumor-directed immunotherapies. The company was founded by Ehud Marom in 2010 and is headquartered in Jerusalem, IL.

Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel.

Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel.

Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel.